Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

Alcon announced it had acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases.